Novartis COPD Filing Coming in 2014, Phase III Data Is Good News for LAMA/LABA Combos

Drug Industry Daily
Novartis’ inhaled, once-daily chronic obstructive pulmonary disease (COPD) candidate met its primary endpoint in the fifth and final Phase III study, setting up European and Japanese filings in the fourth quarter of this year and an FDA filing by the end of 2014.

To View This Article:


Subscribe To Drug Industry Daily